梗死模式对替格瑞洛-阿司匹林联合溶栓疗效的影响:TAPIS亚组分析
本研究为TAPIS试验的亚组分析,纳入1307例接受静脉溶栓的中等程度非心源性缺血性卒中患者,按DWI梗死模式分为多发急性梗死(MAIs)和非MAIs。结果显示MAIs预后较差,替格瑞洛-阿司匹林在MAIs中方向性获益且未增加出血,但主要交互作用未达显著。
要点
- MAIs患者90天良好预后率低于非MAIs(58.9% vs 69.2%)。
- 替格瑞洛-阿司匹林在MAIs中良好预后率64.4% vs 53.4%,RR 1.21。
- 症状性颅内出血率低,MAIs中0.5% vs 1.0%,非MAIs中0.2% vs 0.2%。
核心结论
- 在接受溶栓的中等程度非心源性卒中患者中,MAIs与较差功能结局相关。
- 早期替格瑞洛-阿司匹林在MAIs患者中显示方向一致的获益且无额外出血,但主要交互作用不显著。
研究设计与样本
- TAPIS试验的亚组分析,中国60中心随机双盲试验。
- 纳入1307例18-80岁非心源性卒中(NIHSS 4-10)且在发病4.5小时内接受静脉溶栓的患者。
- 随机在6小时内接受替格瑞洛-阿司匹林或安慰剂,DWI模式中心判读为MAIs或非MAIs。
主要发现
- 409例(31.3%)为MAIs,898例(68.7%)为非MAIs(其中20.8% DWI阴性,79.2%单发梗死)。
- MAIs与较差预后相关:良好预后58.9% vs 69.2%,调整RR 0.92(95% CI 0.84-1.00)。
- 替格瑞洛-阿司匹林在MAIs中良好预后64.4% vs 53.4%,RR 1.21(95% CI 1.02-1.42);非MAIs中71.2% vs 67.1%,RR 1.06(95% CI 0.97-1.16);P交互=0.18。
- 早期神经功能改善存在显著异质性(P交互=0.02);调整补救替罗非班后主要结局交互作用名义显著(P=0.04)。
- 症状性颅内出血:MAIs中1/205(0.5%)vs 2/204(1.0%);非MAIs中1/448(0.2%)vs 1/450(0.2%)。
关键数值与推荐
- 主要疗效结局为90天改良Rankin量表评分0-1分。
- 安全性结局为症状性颅内出血。
临床怎么用
- DWI梗死模式可能作为影像生物标志物指导早期再灌注后的抗血小板治疗。
- 对于MAIs患者,早期替格瑞洛-阿司匹林可能带来获益且不增加出血风险。
局限性
- 主要交互作用未达统计学显著,结果仅为假设生成性。
- 亚组分析设计,需未来试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether diffusion‑weighted imaging infarction patterns influence the efficacy and safety of early oral ticagrelor‑aspirin with intravenous thrombolysis in moderate acute ischemic stroke is uncertain. We assessed treatment effects by infarction pattern in this thrombolysis setting. METHODS: This was a subgroup analysis of the TAPIS trial (Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis in Patients With Ischemic Stroke), a 60-center, randomized, double‑blind trial in China. Patients aged 18 to 80 years with noncardioembolic stroke (National Institutes of Health Stroke Scale score 4-10) who received intravenous thrombolysis within 4.5 hours of onset were randomized within 6 hours to ticagrelor‑aspirin or placebo. Diffusion‑weighted imaging patterns were centrally adjudicated as multiple acute infarcts (MAIs; ≥2 lesions) or non‑MAIs (single infarction or diffusion‑weighted imaging-negative). The primary efficacy outcome was modified Rankin Scale score of 0 to 1 at 90 days; safety outcome was symptomatic intracranial hemorrhage. Treatment‑by‑pattern interaction was assessed. RESULTS: Among 1307 patients (94.6% of full analysis set; median age, 65.5 years; 71.2% men; median National Institutes of Health Stroke Scale score, 6.0), 409 (31.3%) had MAIs and 898 (68.7%) non‑MAIs (20.8% diffusion‑weighted imaging-negative, 79.2% single infarction). MAIs were associated with poorer prognosis than non‑MAIs (excellent outcome: 58.9% versus 69.2%; adjusted risk ratio, 0.92 [95% CI, 0.84-1.00]). Ticagrelor‑aspirin was associated with a higher likelihood of excellent outcome versus placebo in MAIs (64.4% versus 53.4%; risk ratio, 1.21 [95% CI, 1.02-1.42]), whereas no significant benefit was observed in non‑MAIs (71.2% versus 67.1%; risk ratio, 1.06 [95% CI, 0.97-1.16]; Pinteraction=0.18). Early neurological improvement showed significant heterogeneity by infarction pattern (Pinteraction=0.02); the treatment‑by‑pattern interaction for the primary outcome was nominally significant after adjusting for rescue tirofiban use (P=0.04). Symptomatic intracranial hemorrhage occurred in MAIs: 1 of 205 (0.5%) versus 2 of 204 (1.0%); non‑MAIs: 1 of 448 (0.2%) versus 1 of 450 (0.2%). CONCLUSIONS: In thrombolyzed patients with moderate noncardioembolic stroke, MAIs were associated with poorer functional outcomes. Early ticagrelor‑aspirin showed directionally consistent benefits without excess bleeding in patients with MAIs, though the primary interaction was not significant. These hypothesis‑generating findings may inform future trials of diffusion‑weighted imaging infarction pattern as an imaging biomarker to guide antiplatelet therapy in early reperfusion. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06316570.
引用
- Zi X, He Y, Chen G, et al. Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis. Stroke. 2026. PMID: 42689322. doi:10.1161/STROKEAHA.126.057001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。